ima950
Vaccineexperimental
Clinical trial activity
4 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2010 (NCT01222221)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ima950
- ima 950
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02924038 | Phase 1 | Jan 1, 2017 | University of California, San Francisco |
| NCT01920191 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2013 | immatics Biotechnologies GmbH, Oncovir, Inc., University of Geneva |
| NCT01403285 | Phase 1 | Aug 1, 2011 | immatics Biotechnologies GmbH, National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT01222221 | Phase 1 | Jul 1, 2010 | Cancer Research UK, immatics Biotechnologies GmbH, University of Glasgow |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| immatics Biotechnologies GmbH | For profit | 3 | 1 | 2 | 2010 |
| Cancer Research UK | Academic/Hospital | 1 | 1 | 1 | 2010 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2011 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2011 |
| Oncovir, Inc. | For profit | 1 | 0 | 1 | 2013 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Geneva | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Glasgow | Academic/Hospital | 1 | 0 | 1 | 2010 |
8 organizations
Page 1 / 1